Together, the cancers account for about 30 percent of the estimated 15,780 cases of pediatric cancers diagnosed annually in the U.S. Five - year
survival for pediatric patients with these cancers is now 90 percent or better, according to the American Cancer Society.
The
survival difference between the two groups was not statistically significant, but investigators said the results point to a possible benefit of GO treatment
for some
pediatric AML
patients whose cancer remained following chemotherapy.